February 21, 2018 / 8:08 AM / 9 months ago

BRIEF-Biohaven Announces License Agreement With Catalent For Zydis ODT With Small Molecule Cgrp Receptor Antagonists

Feb 21 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:

* BIOHAVEN ANNOUNCES EXCLUSIVE LICENSE WITH CATALENT FOR ZYDIS® ORALLY DISSOLVING TABLET WITH SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS

* ENTERED LICENSE AGREEMENT CATALENT U.K. SWINDON ZYDIS LTD TO PROVIDE CATALENT'S ZYDIS ODT FAST-DISSOLVING FORMULATION

* AGREEMENT FOR DEVELOPMENT OF BIOHAVEN'S LEAD CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST PRODUCT CANDIDATE, RIMEGEPANT

* AGREEMENT ALSO PROVIDES EXCLUSIVE RIGHTS FOR DEVELOPING SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS WITH ZYDIS ODT TECHNOLOGY Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below